This page is an archive. Its content may no longer be accurate and was last updated on the original publication date. It is intended for reference and as a historical record only. For hep C questions, call Help4Hep BC at 1-888-411-7578.
August 20, 2015: Today we received news that another upcoming drug, daclatasvir (Daklinza™) from Bristol-Myers Squibb, has received a Notice of Compliance from Health Canada. It is already being considered for coverage by British Columbia’s Pharmacare, though it has not yet been approved. This drug is unique in its potential to mix and match with other drugs in order to treat a variety of genotypes, including hard-to-treat genotype 3 (combined with Gilead’s sofosbuvir [Sovaldi™]). Though BMS could have combined it with one or more of its own drugs, it chose to submit daclatasvir on a stand-alone basis which could be combined with drugs from other companies, which is what HepCBC has been advocating that pharmaceuticals should do whenever possible, in order to quickly give physicians the option to treat individual patients according to their unique circumstances and the most recent clinical research.
Read full press release:
http://www.newswire.ca/news-releases/health-canada-approves-daklinza-daclatasvir-for-the-treatment-of-chronic-hepatitis-c-infection-across-multiple-genotypes-including-genotype-3-522375441.html